// App-Quantinova.ai

: Long-term Efficacy and Safety of Risankizumab (RZB) for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Beyond 4 Years of Follow-up

Researchers

Presenter

  • Kim A Papp

Principal Investigators

  • Mark G Lebwohl

  • Lluís Puig

  • Mamitaro Ohtsuki

  • Stefan Beissert

  • Jiewei Zeng

  • Simone Rubant

  • Ranjeeta Sinvhal

  • Ahmed M. Soliman

  • Stefan Beeck

  • Craig Leonardi

Medical Centers

  • K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Jichi Medical University, Tochigi, Japan

  • Dept of Dermatology, University-Hospital Carl Gustav Carus, Dresden, Germany

  • AbbVie, Inc., North Chicago, IL

  • Central Dermatology, Richmond Heights, MO, USA

Locations

  • United States

  • Germany

  • Spain

  • Turkey

  • Japan

  • France

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • Interleukin-23

Drug/Treatment

  • Risankizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT03047395

  • NCT03255382

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved